Table 1.
Baseline Characteristics of Participants.
| Baseline characteristic | Daily Trial | Nocturnal Trial | ||
|---|---|---|---|---|
|
| ||||
| 3x/wk | 6x/wk | 3x/wk | 6x/wk | |
|
| ||||
| No. of patients | 101 | 117 | 40 | 41 |
|
| ||||
| Age (y) | 51.9 ± 13.8 | 48.9 ± 13.4 | 54.9 ± 12.2 | 51.1 ± 14.5 |
|
| ||||
| Male sex | 61 (60.4) | 72 (61.5%) | 26 (65.0%) | 27 (65.9%) |
|
| ||||
| Race /Ethnicity | ||||
| Black | 53 (44.2%) | 49 (39.2%) | 11 (26.2%) | 12 (26.7%) |
| White | 46 (38.3%) | 43 (34.4%) | 21 (50.0%) | 27 (60.0%) |
| Native American, Aboriginal Canadian, Alaskan Native, First Nation | 4 (3.3%) | 4 (3.2%) | 2 (4.8%) | 1 (2.2%) |
| Asian | 5 (4.2%) | 11 (8.8%) | 7 (16.7%) | 5 (11.1%) |
| Native Hawaiian or other | 3 (2.5%) | 1 (0.8%) | 0 (0%) | 0 (0%) |
| Pacific Islander | ||||
| Other/Mixed/Unknown | 9 (7.5%) | 17 (13.6%) | 1 (2.4%) | 0 (0%) |
| Hispanic/Latino Ethnicity* | 31 (26%) | 38 (30%) | 0 (0%) | 0 (0%) |
|
| ||||
| Primary language English | 85 (84.2%) | 88 (75.2%) | 34 (85.0%) | 37 (90.0%) |
|
| ||||
| ESRD vintage (y) | 3.02 (0.6–12.5) | 3.85 (0.6–17.3) | 0.5 (0.08–6.1) | 1.3 (0.09–12.6) |
|
| ||||
| Education | ||||
|
| ||||
| < High school graduate | 20 (20.0%) | 27 (23.5%) | 5 (12.5%) | 8 (20.0%) |
|
| ||||
| High school graduate | 29 (29.0%) | 25 (21.7%) | 9 (22.5%) | 11 (27.5%) |
|
| ||||
| Post high school | 51 (51.0%) | 63 (54.8%) | 26 (65.0%) | 21 (52.5%) |
|
| ||||
| Diabetes | 42 (41.6%) | 48 (41.0%) | 18 (45.0%) | 16 (39.0%) |
|
| ||||
| Stroke | 6 (5.9%) | 8 (6.8%) | 1 (2.5%) | 1 (2.4%) |
|
| ||||
| Charlson comorbidity index | 1.5 ± 1.8 | 1.4 ± 1.6 | 1.6 ± 1.7 | 1.2 ± 1.3 |
|
| ||||
| Beck depression index | 12.7 ± 9.9 | 12.5 ± 8.6 | 11.5 ± 8.7 | 11.7 ± 8.2 |
|
| ||||
| Predialysis SBP (mm Hg) | 146 ± 18 | 147 ± 19 | 154 ± 22 | 144 ± 13 |
|
| ||||
| Predialysis DBP (mm Hg) | 78 ± 12 | 81 ± 11 | 83 ± 14 | 80 ±11 |
|
| ||||
| Hemoglobin (g/dL) | 12.0 ± 1.3 | 11.8 ± 1.2 | 11.9 ± 1.1 | 11.6 ± 1.1 |
|
| ||||
| Albumin (g/dL) | 4.0 ± 0.5 | 3.9 ± 0.4 | 3.9 ± 0.5 | 3.9 ± 0.5 |
|
| ||||
| Anticonvulsant | 22 (21.8%) | 22 (18.8%) | 8 (20.0%) | 7 (18.4%) |
|
| ||||
| Antidepressant | 13 (12.9%) | 14 (15.8%) | 9 (22.5%) | 9 (23.7%) |
|
| ||||
| Antihistamine | 24 (23.8%) | 21 (18.0%) | 14 (35.0%) | 18 (43.9%) |
|
| ||||
| Benzodiazepine | 10 (9.9%) | 15 (12.8%) | 7 (17.5%) | 7 (17.1%) |
|
| ||||
| Opioid | 15 (14.9%) | 21 (18.0%) | 7 (17.5%) | 10 (24.4%) |
Note: Values are for participants in the Frequent Hemodialysis Network Trials who completed baseline and at least 1 follow-up cognitive test. Values for categorical variables are given as number (percentage); values for continuous variables are given as mean +/− SD or median (range).
Abbreviations: ESRD, end-stage renal disease; SBP - systolic blood pressure, DBP - diastolic blood pressure
*
Persons in this category may also be counted in other categories.